‘Extraordinary’ empagliflozin CV findings lauded

Australian endocrinologists have welcomed the results of a new study that shows empagliflozin could slash mortality rates and cardiovascular problems in patients with type 2 diabetes at high CV risk.

The EMPA-REG OUTCOME trial of over 7000 patients shows patients taking empagliflozin with standard treatment report a 38% relative risk reduction of death from cardiovascular causes compared with patients on placebo.